Contemporary Systemic Therapy Intensification for Prostate Cancer : A Review for General Practitioners in Oncology
Prostate cancer accounts for a significant proportion of cancer diagnoses in Canadian men. Over the past decade, the therapeutic landscape for the management of metastatic prostate cancer has undergone rapid changes. Novel strategies use hormonal agents, chemotherapy, homologous recombination repair inhibitors, and radioligand therapy or combination strategies in addition to androgen deprivation therapy. In this review, we summarize the available data addressing key therapeutic areas along the disease continuum and focus on practical aspects for general practitioners in oncology managing patients with metastatic prostate cancer.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:31 |
|---|---|
| Enthalten in: |
Current oncology (Toronto, Ont.) - 31(2024), 2 vom: 15. Feb., Seite 1047-1062 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Batra, Anupam [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 26.02.2024 Date Revised 26.02.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3390/curroncol31020078 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368820548 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368820548 | ||
| 003 | DE-627 | ||
| 005 | 20240229155535.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240229s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/curroncol31020078 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1306.xml |
| 035 | |a (DE-627)NLM368820548 | ||
| 035 | |a (NLM)38392072 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Batra, Anupam |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Contemporary Systemic Therapy Intensification for Prostate Cancer |b A Review for General Practitioners in Oncology |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.02.2024 | ||
| 500 | |a Date Revised 26.02.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Prostate cancer accounts for a significant proportion of cancer diagnoses in Canadian men. Over the past decade, the therapeutic landscape for the management of metastatic prostate cancer has undergone rapid changes. Novel strategies use hormonal agents, chemotherapy, homologous recombination repair inhibitors, and radioligand therapy or combination strategies in addition to androgen deprivation therapy. In this review, we summarize the available data addressing key therapeutic areas along the disease continuum and focus on practical aspects for general practitioners in oncology managing patients with metastatic prostate cancer | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a ARAT | |
| 650 | 4 | |a BRCA1/2 | |
| 650 | 4 | |a CAGPO | |
| 650 | 4 | |a Canadian Association of General Practitioners in Oncology | |
| 650 | 4 | |a PARP inhibitors | |
| 650 | 4 | |a PSMA | |
| 650 | 4 | |a androgen receptor axis-targeted drugs | |
| 650 | 4 | |a breast cancer gene 1/2 | |
| 650 | 4 | |a docetaxel | |
| 650 | 4 | |a poly ADP ribose polymerase inhibitors | |
| 650 | 4 | |a prostate cancer | |
| 650 | 4 | |a prostate-specific membrane antigen | |
| 650 | 7 | |a Androgen Antagonists |2 NLM | |
| 650 | 7 | |a Poly(ADP-ribose) Polymerase Inhibitors |2 NLM | |
| 700 | 1 | |a Glick, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Valdes, Mario |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current oncology (Toronto, Ont.) |d 1998 |g 31(2024), 2 vom: 15. Feb., Seite 1047-1062 |w (DE-627)NLM09444482X |x 1718-7729 |7 nnns |
| 773 | 1 | 8 | |g volume:31 |g year:2024 |g number:2 |g day:15 |g month:02 |g pages:1047-1062 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/curroncol31020078 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 31 |j 2024 |e 2 |b 15 |c 02 |h 1047-1062 | ||